(Q43590396)

25 November 2017

Bivalent inhibition of human beta-tryptase (English)

1 reference

25 November 2017

Schaschke N

1

1 reference

25 November 2017

Matschiner G

2

1 reference

25 November 2017

Zettl F

3

1 reference

25 November 2017

Marquardt U

4

1 reference

25 November 2017

Bergner A

5

1 reference

25 November 2017

Bode W

6

1 reference

25 November 2017

Sommerhoff CP

7

1 reference

25 November 2017

Moroder L

8

1 reference

25 November 2017

1 April 2001

1 reference

25 November 2017

Chemistry and Biology

1 reference

25 November 2017

8

1 reference

25 November 2017

4

1 reference

25 November 2017

313-327

1 reference

Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Strength in numbers: non-natural polyvalent carbohydrate derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Towards the development of antimicrobial drugs acting by inhibition of pathogen attachment to host cells: a need for polyvalency

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Synthesis and characterization of bivalent peptide ligands targeted to G-protein-coupled receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Spanning binding sites on allosteric proteins with polymer-linked ligand dimers

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

A new class of bradykinin antagonists: synthesis and in vitro activity of bissuccinimidoalkane peptide dimers

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Potent bivalent thrombin inhibitors: replacement of the scissile peptide bond at P(1)-P(1)' with arginyl ketomethylene isosteres

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Design and evaluation of novel bivalent thrombin inhibitors based on amidinophenylalanines

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

The influence of polyvalency on the binding properties of antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Evaluation of group contributions to ligand binding

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

On the attribution and additivity of binding energies

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

A trivalent system from vancomycin.D-ala-D-Ala with higher affinity than avidin.biotin

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

The structure of a complex of recombinant hirudin and human alpha-thrombin

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Structure of 20S proteasome from yeast at 2.4 A resolution

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Human beta-tryptase is a ring-like tetramer with active sites facing a central pore

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

The structure of the human betaII-tryptase tetramer: fo(u)r better or worse

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Bivalency as a principle for proteasome inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Synthesis of bivalent inhibitors of eucaryotic proteasomes

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

The human mast cell tryptase tetramer: a fascinating riddle solved by structure

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Cyclodextrins as templates for the presentation of protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Beta-cyclodextrin/epoxysuccinyl peptide conjugates: a new drug targeting system for tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

PyBOP®: A new peptide coupling reagent devoid of toxic by-product

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Regulation of human mast cell tryptase. Effects of enzyme concentration, ionic strength and the structure and negative charge density of polysaccharides

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Regulation of the activity of secreted human lung mast cell tryptase by mast cell proteoglycans

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Inactivation of human lung tryptase: evidence for a re-activatable tetrameric intermediate and active monomers

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Spontaneous inactivation of human lung tryptase as probed by size-exclusion chromatography and chemical cross-linking: dissociation of active tetrameric enzyme into inactive monomers is the primary event of the entire process

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Structural basis of the activation and action of trypsin

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

The transition of bovine trypsinogen to a trypsin-like state upon strong ligand binding. II. The binding of the pancreatic trypsin inhibitor and of isoleucine-valine and of sequentially related peptides to trypsinogen and to p-guanidinobenzoate-tryp

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Contributions of tryptophan side chains to the circular dichroism of globular proteins: exciton couplets and coupled oscillators

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Mast cell tryptases: examination of unusual characteristics by multiple sequence alignment and molecular modeling

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Structural changes associated with the spontaneous inactivation of the serine proteinase human tryptase

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Of mites and men: trypsin-like proteases in the lungs

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Mast cell tryptase potentiates histamine-induced contraction in human sensitized bronchus

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Quantitative locus analysis of airway hyperresponsiveness in A/J and C57BL/6J mice

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Natural disruption of the mouse mast cell protease 7 gene in the C57BL/6 mouse.

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Potent selective nonpeptidic inhibitors of human lung tryptase.

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Syntheses and evaluation of amidinobenzofuran derivatives as tryptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Dibasic inhibitors of human mast cell tryptase. Part 1: synthesis and optimization of a novel class of inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Dibasic inhibitors of human mast cell tryptase. Part 2: structure-activity relationships and requirements for potent activity

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1074-5521%2801%2900011-4

7 January 2021

10.1016/S1074-5521(01)00011-4

Identifiers

DOI

1 reference

25 November 2017

1 reference